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Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are speciﬁc indicators of patients
with dermatomyositis, particularly clinically amyopathic dermatomyositis (CADM). CADM is occasionally
accompanied by fatal, treatment-resistant, rapidly-progressive interstitial lung disease (RP-ILD). All
previous reports showed that histopathological ﬁndings in RP-ILD with anti-MDA5 antibody-positive
CADM indicated diffuse alveolar damage (DAD). This is the ﬁrst report describing a non-DAD pattern in
RP-ILD with anti-MDA5 antibody-positive CADM, which was improved by immunosuppressive therapy.
This case may be a milder clinical phenotype than a typical DAD pattern in RP-ILD with anti-MDA5
antibody-positive CADM.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Anti-melanoma differentiation-associated gene 5 (MDA5) anti-
bodies are speciﬁc indicators of patients with dermatomyositis,
particularly clinically amyopathic dermatomyositis (CADM) [1e6].
CADM is occasionally accompanied by fatal, treatment-resistant,
rapidly-progressive interstitial lung disease (RP-ILD) [7,8]. A few
reports have shown that diffuse alveolar damage (DAD) is a histo-
pathological ﬁnding in RP-ILD with anti-MDA5 antibody-positive-associated gene 5; CADM,
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Ltd. This is an open access article uCADM. However, these ﬁndings were conﬁrmed only at autopsy
[9,10]. To our knowledge, this is the ﬁrst case report to show a non-
DAD pattern in RP-ILD with anti-MDA5 antibody-positive CADM,
which was improved by immunosuppressive therapy.2. Case report
A 32-year-old woman was referred to our hospital with a 4-
week history of fever, cough, and erythematous eruptions. She was
a never-smoker and had no signiﬁcant medical history or envi-
ronmental risk for respiratory disease. Her physical examination
revealed a fever (38.3 C), facial erythema and heliotrope rash
(Fig. 1a), erythema over the V area of the neck (Fig. 1b), scaly ery-
themawith ulceration over the elbow (Fig. 1c), knee, and dorsum of
her hands (Gottron’s sign) (Fig.1d), and skin thickening on the sides
of her ﬁngers (mechanic hands). There were no signs of muscle
weakness. Fine crackles were heard in the bilateral lower lung
ﬁelds. Arterial blood gas analysis showed normal partial pressure of
oxygen and carbon dioxide (73.5 and 38.6 Torr, respectively). The
alveolar-arterial oxygen difference was 28 mmHg. The serum levels
of C-reactive protein and creatine kinase were not elevated. The
serum levels of Krebs von den Lungen-6, lactate dehydrogenase,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Physical ﬁndings suggestive of clinically amyopathic dermatomyositis. a) facial erythema and heliotrope rash; b) erythema over the V area of the neck; c) scaly erythema
with ulceration over the elbow; d) Gottron’s sign.
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and 1269 ng/ml, respectively). Anti-MDA5 antibody was detected
(40.7 U/ml > 8 U/ml). Other autoantibodies suggesting autoim-
mune disorders were not detected. A chest computed tomography
(CT) scan showed peribronchovascular ground-glass opacities and
bilateral subpleural reticular opacities (Fig. 2). A pulmonary func-
tion test indicated normal predicted value for forced vital capacity
(%FVC) and decreased predicted value for diffusing capacity of the
lung for carbon monoxide (%DLco) (%FVC 86.5%; %DLco 71.9%).
Bronchoalveolar lavage was performed in right B9. The total cell
count was 1.38  105 cells m1, with a normal cellular proﬁle andFig. 2. Chest computed tomography. Peribronchovascular ground-glass opacities and
bilateral subpleural reticular opacities.CD4/CD8 ratio (the percentage of neutrophils and lymphocytes
were 2 and 0%, respectively). Microbial culture results from the
sputum and bronchoalveolar lavage ﬂuid were negative. Six-min
walk distance (6MWD) was 285 m, with 96% of minimum arterial
oxygen saturation measured by pulse oximetry. The modiﬁed
medical research council dyspnea scale (MMRC) was 2. Magnetic
resonance imaging of inferior retinaculum of extensor muscles
demonstratedmuscle edema that was consistent withmyositis. In a
muscle biopsy, ﬁndings of perivascular inﬂammatory inﬁltrate and
perifascicular muscle ﬁber atrophy were obtained.
While the deﬁnition of CADM by Sontheimer [5] requires that
skin disease be present for 6 months without the development of
muscle disease, Sontheimer et al. [6] has also described a subset of
patients with CADM inwhom fatal ILD developed within the ﬁrst 6
months of their disease course. Although the disease duration was
short in our patient, a presumptive diagnosis of CADM with RP-ILD
wasmade on the basis of the described ﬁndings. Oneweek after the
ﬁrst visit, in order to determine the histopathological pattern, we
performed video-assisted thoracic surgical lung biopsy (SLB) (right
S5, 8, 9).
The lesion was characterized by diffuse mild interstitial ﬁbrosis
and inﬂammatory cell inﬁltration mostly of lymphocytes, and the
changes were homogeneous, as in a nonspeciﬁc interstitial pneu-
monia (NSIP) pattern (Fig. 3a). Meanwhile, mild peripheral accen-
tuation and inﬂammatory changes around the respiratory
bronchioles were also seen. There were accumulations of foamy
macrophages and a few neutrophils in the airspace (Fig. 3b), and
subacute changes such as scant airspace ﬁbrin and scattered Mas-
son bodies as a minor component of the pathology (Fig. 3c, d).
Fig. 3. Histopathological ﬁndings in lung biopsy specimen. a) diffuse involvement in secondary lobule with mild peripheral accentuation [haematoxylin-eosin (HE) stain]; b)
accumulation of foamy macrophages accentuated in the periphery of the lobule along with a few neutrophils [HE stain]; c) no hyaline membrane or extensive ﬁbrin are seen, but
rare and scant airspace ﬁbrin is found [HE stain]; d) Scattered Masson bodies as organizing pneumonia incorporating surrounding alveolar ducts in less than 20% of area [Elastica
van Gieson stain]. Scale bars: 900 mm (a), 200 mm (b, c, d).
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airspace ﬁbrin, and extensive interstitial edema were not found.
One week after SLB, two cycles of methylprednisolone pulse
therapy (1000mg day1 for 3 days) were initiated, followed by
10 mg of prednisolone and 5 mg of tacrolimus daily. This was
associated with a signiﬁcant resolution of symptoms within 1
month (MMRCwas 1). The serum ferritin level decreased to 648 ng/
ml, while %FVC increased to 96.0%. The 6MWD was improved to
560 m. These effects were maintained during the ﬁrst year of
treatment. No adverse events were observed.
3. Discussion
To our knowledge, this is the ﬁrst case to show a non-DAD
pattern in a survivor with RP-ILD and anti-MDA5 antibody-posi-
tive CADM. The important point here is that the histopathological
ﬁndings indicated non-DAD patternwith a favorable clinical course.
All previous reports showed that histopathological ﬁndings in RP-
ILD with anti-MDA5 antibody-positive CADM indicated DAD
[9,10]. However, our lung biopsy specimens showed diffuse and
homogeneous inﬂammatory cell inﬁltration similar to NSIP with
subacute inﬂammatory ﬁndings, which was different from DAD.
These differences may have resulted from the timing of the lung
biopsy or a difference in the type of interstitial pneumonia, which
inﬂuences prognosis. We performed surgical lung biopsy one week
after the ﬁrst visit. Therefore, our lung specimens may reﬂect the
early phase of RP-ILD, which may progress to DAD. Anotherpossibility is that there may be some heterogeneity with regards to
ILD pattern in patients with RP-ILD and anti-MDA5 antibody-pos-
itive CADM [11]. Further studies are needed to clarify whether or
not histopathologic pattern is associated with prognosis in patients
with RP-ILD and anti-MDA5 antibody-positive CADM.
In our patient, both onset and histopathological ﬁndings were
atypical for NSIP. Recent guidelines classiﬁed NSIP into chronic
ﬁbrosing interstitial pneumonia; however, the present case showed
subacute onset [12]. As for histopathological ﬁndings, subacute
changes were atypical for NSIP. Taken together, we diagnosed the
histopathological pattern as unclassiﬁable interstitial pneumonia.
Another important point in this case is the treatment. Previous
studies showed that anti-MDA5 antibody is associated with
increased mortality in CADM [1,2,4]. Furthermore, some studies
showed that high levels of ferritin are associatedwith the prognosis
of anti-MDA5 antibody-positive CADM [2,13]. For this reason, a
combination therapy including intravenous cyclophosphamide
(IVCY) is recommended in RP-ILD patients with hyperferritinemia
(>500 ng/ml) and/or anti-MDA5 antibody [14]. Although our pa-
tient had some poor prognostic factors, improvements were seen in
symptoms, pulmonary function, 6MWD, and serum ferritin levels
with only corticosteroids and tacrolimus. Wilkes et al. [15] showed
that tacrolimus is a well-tolerated and effective therapy for man-
aging refractory ILD and myositis in anti-aminoacyl-transfer RNA
synthetase positive patients. Another study showed that combi-
nation therapy including IVCY was more frequently received in the
dead subset than in the living subset of patients with anti-MDA5
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tients with anti-MDA5 antibody-positive CADM may not need
strong immunosuppressive therapy.
In conclusion, this is the ﬁrst report describing a non-DAD
pattern in RP-ILD with anti-MDA5 antibody-positive CADM,
which was improved by immunosuppressive therapy. This case
may be a milder clinical phenotype than a typical DAD pattern in
RP-ILD with anti-MDA5 antibody-positive CADM. Further studies
are needed to determine the mechanisms of lung injury and an
appropriate treatment of RP-ILD with anti-MDA5 antibody-positive
CADM.
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